StartupHub Opportunity: Targeted C. difficile Therapeutics скачать в хорошем качестве

StartupHub Opportunity: Targeted C. difficile Therapeutics

Innovations in anti-infective therapy are transforming how we treat Clostridioides difficile infection (CDI) while preserving the natural microbiome. This precision technology uses an orally delivered antisense oligonucleotide designed to selectively target and eliminate C. difficile without harming beneficial bacteria or human cells. By focusing on a microbiome-sparing strategy, this approach avoids the limitations of traditional antibiotics, including resistance and disruption of protective gut flora. In preclinical studies, the technology demonstrated complete eradication of dominant C. difficile strains and significant improvement in intestinal health. Join us in advancing next-generation infectious disease treatments that offer safer, more targeted solutions for patients facing serious gastrointestinal infections. This opportunity features Gayatri Vedantam, PhD, Professor, School of Animal and Comparative Biomedical Sciences at the College of Agriculture, Life and Environmental Sciences at the University of Arizona, inventor and scientific lead behind the technology. View this and other high-potential technologies on the Tech Launch Arizona StartupHub.